RU2017104909A3 - - Google Patents

Download PDF

Info

Publication number
RU2017104909A3
RU2017104909A3 RU2017104909A RU2017104909A RU2017104909A3 RU 2017104909 A3 RU2017104909 A3 RU 2017104909A3 RU 2017104909 A RU2017104909 A RU 2017104909A RU 2017104909 A RU2017104909 A RU 2017104909A RU 2017104909 A3 RU2017104909 A3 RU 2017104909A3
Authority
RU
Russia
Application number
RU2017104909A
Other languages
Russian (ru)
Other versions
RU2704811C2 (ru
RU2017104909A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017104909A publication Critical patent/RU2017104909A/ru
Publication of RU2017104909A3 publication Critical patent/RU2017104909A3/ru
Application granted granted Critical
Publication of RU2704811C2 publication Critical patent/RU2704811C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/244Lanthanides; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2017104909A 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства RU2704811C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17 2014-07-17
US62/025,861 2014-07-17
PCT/US2015/040869 WO2016011328A1 (en) 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019133284A Division RU2019133284A (ru) 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства

Publications (3)

Publication Number Publication Date
RU2017104909A RU2017104909A (ru) 2018-08-17
RU2017104909A3 true RU2017104909A3 (https=) 2019-01-28
RU2704811C2 RU2704811C2 (ru) 2019-10-31

Family

ID=55079076

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019133284A RU2019133284A (ru) 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
RU2017104909A RU2704811C2 (ru) 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2019133284A RU2019133284A (ru) 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства

Country Status (9)

Country Link
EP (2) EP3628308A1 (https=)
JP (2) JP6706255B2 (https=)
CN (2) CN111184733A (https=)
AU (1) AU2015289504B2 (https=)
BR (1) BR112017000800A8 (https=)
CA (1) CA2955384C (https=)
MX (1) MX387363B (https=)
RU (2) RU2019133284A (https=)
WO (1) WO2016011328A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512761B2 (en) 2009-12-02 2019-12-24 Renovorx, Inc. Methods for delivery of therapeutic materials to treat pancreatic cancer
WO2014197362A1 (en) 2013-06-03 2014-12-11 Ramtin Agah Devices, methods and kits for delivery of therapeutic materials to a pancreas
BR112017000800A8 (pt) * 2014-07-17 2023-04-25 Biocurity Holdings Inc Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico
WO2017174437A1 (en) * 2016-04-05 2017-10-12 Hospital Clínic De Barcelona Ceria nanoparticles for use in the treatment of hepatocellular carcinoma
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3609329A4 (en) * 2017-04-12 2021-03-17 Bhagwandin, Vikash J. COMPOSITIONS, PACKAGED MEDICINAL PRODUCTS AND METHODS OF USE OF POSACONAZOLE FOR RESISTANT TUMORS Awareness
BR112019022280A2 (pt) * 2017-04-28 2020-05-19 Seattle Genetics Inc tratamento de cânceres de her2 positivo
US11052224B2 (en) 2017-05-18 2021-07-06 Renovorx, Inc. Methods for treating cancerous tumors
US10695543B2 (en) 2017-05-18 2020-06-30 Renovorx, Inc. Methods for treating cancerous tumors
US12290564B2 (en) 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
WO2020069292A1 (en) * 2018-09-28 2020-04-02 The Regents Of The University Of Colorado, A Body Corporate Methods for preventing and treating pulmonary inflammation and fibrosis
RU2699670C1 (ru) * 2018-11-16 2019-09-09 Объединенный Институт Ядерных Исследований (Оияи) Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов
EP4125364A4 (en) * 2020-04-30 2024-09-04 University of Central Florida Research Foundation, Inc. Dispensable nanoparticle based composition for disinfection
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548B (zh) 2021-08-27 2026-03-03 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20250160163A (ko) 2023-02-27 2025-11-11 아센타위츠 파마슈티컬즈 리미티드 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099798A (en) 1997-10-31 2000-08-08 Nanogram Corp. Ultraviolet light block and photocatalytic materials
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US8703200B2 (en) 2005-04-29 2014-04-22 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
WO2007002662A2 (en) * 2005-06-27 2007-01-04 Edward Via Virginia College Of Osteopathic Medicine Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US9393439B2 (en) * 2010-03-01 2016-07-19 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
US9415065B2 (en) * 2012-04-04 2016-08-16 University Of Central Florida Research Foundation, Inc. Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
IN2014DN10550A (https=) * 2012-06-13 2015-08-21 Cerion Entpr Llc
EP2928877B1 (en) * 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
EP3134347B1 (en) * 2014-04-25 2019-04-10 The Regents of The University of Michigan Nanoparticle for use in the therapy of cancer
BR112017000800A8 (pt) * 2014-07-17 2023-04-25 Biocurity Holdings Inc Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico
GB201506381D0 (en) * 2015-04-15 2015-05-27 Isis Innovation Embolization particle

Also Published As

Publication number Publication date
JP2020158507A (ja) 2020-10-01
BR112017000800A8 (pt) 2023-04-25
JP2017521499A (ja) 2017-08-03
CN106604719A (zh) 2017-04-26
MX387363B (es) 2025-03-18
EP3169312A4 (en) 2017-12-27
JP6706255B2 (ja) 2020-06-03
WO2016011328A1 (en) 2016-01-21
EP3169312A1 (en) 2017-05-24
CN111184733A (zh) 2020-05-22
BR112017000800A2 (pt) 2018-07-03
RU2019133284A (ru) 2019-12-05
RU2704811C2 (ru) 2019-10-31
EP3169312B1 (en) 2020-09-02
CN106604719B (zh) 2019-11-26
CA2955384C (en) 2024-03-12
AU2015289504A1 (en) 2017-02-23
MX2017000578A (es) 2017-07-20
AU2015289504B2 (en) 2020-12-17
RU2017104909A (ru) 2018-08-17
EP3628308A1 (en) 2020-04-01
CA2955384A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
BR112016016900A2 (https=)
BR112016017696A2 (https=)
BR112016017131A2 (https=)
BR112016015605A2 (https=)
BR112016016546A2 (https=)
BR112016016741A2 (https=)
RU2017104909A3 (https=)
BR112016015845A2 (https=)
BR112016017226A2 (https=)
BR112016015386A2 (https=)
BR112016015385A2 (https=)
BR112016016106A2 (https=)
BR112016017713A2 (https=)
BR112016017660A2 (https=)
BR112016017469A2 (https=)
BR112016018632A2 (https=)
BR112016017502A2 (https=)
BR112016017093A2 (https=)
BR112016016078A2 (https=)
BR112016014619A2 (https=)
AP2017009684A0 (https=)
BR112016030993A2 (https=)
BR112016016575A2 (https=)
BR112016017421A2 (https=)
BR112016015619A2 (https=)

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant